BioVie Inc. (BIVI) stock
BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
$1.00−0.08 (-7.84%)
Close on Nov 17, 2026Market cap $7.51MP/E –Yield –
BioVie r&d expenses
Research and development expenses are spending on new products and technology.
BioVie's R&D Expenses for the twelve months ending Jun 30, 2026 was $13.96M, up 50.7% year over year. For fiscal 2026 it was $13.96M, up 50.7% from the year before. Over ten years it grew 80.6% a year on average. The highest annual figure on record is $33.30M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $13.96M | +50.7% |
| FY2025 | Jun 30, 2025 | $9.27M | -59.9% |
| FY2024 | Jun 30, 2024 | $23.10M | -30.6% |
| FY2023 | Jun 30, 2023 | $33.30M | +92.9% |
| FY2022 | Jun 30, 2022 | $17.26M | +578.2% |
| FY2021 | Jun 30, 2021 | $2.54M | +121.2% |
| FY2020 | Jun 30, 2020 | $1.15M | +14.1% |
| FY2019 | Jun 30, 2019 | $1.01M | +171.8% |
| FY2018 | Jun 30, 2018 | $370.85K | -20.5% |
| FY2017 | Jun 30, 2017 | $466.35K | +1130.5% |
| FY2016 | Jun 30, 2016 | $37.90K | +803.3% |
| FY2015 | Jun 30, 2015 | $4.20K | -91.5% |
| FY2014 | Jun 30, 2014 | $49.42K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $3.58M | +192.4% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $3.18M | +136.2% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $4.27M | -9.3% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $2.94M | +47.5% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $1.22M | -40.4% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $1.34M | -76.4% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $4.70M | -27.3% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $1.99M | -77.6% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $2.05M | -75.3% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $5.70M | -49.1% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $6.47M | -8.0% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $8.88M | +31.1% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $8.30M | +41.3% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $11.20M | +213.0% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $7.03M | +49.2% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $6.77M | +118.8% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $5.87M | +1018.4% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $3.58M | +353.0% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $4.71M | +402.5% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $3.09M | +2966.7% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $525.09K | +256.1% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $789.58K | +123.6% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $938.10K | +170.7% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $100.91K | -70.4% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $147.46K | -46.5% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $353.20K | -11.8% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $346.51K | +261.9% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $341.50K | +635.7% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $275.73K | +47.6% |
| Q1 FY2019CQ3 2018 | Dec 31, 2018 | $400.54K | +857.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $95.74K | +5.8% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $46.42K | -61.3% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $186.84K | +45.3% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $41.85K | -67.1% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $90.48K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $120.04K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $128.56K | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $127.27K | – |
See a number that looks wrong?